PDF(1561 KB)
提高化疗强度对伴IKZF1基因缺失儿童急性淋巴细胞白血病预后的影响
郑湧智, 李健, 乐少华, 郑浩, 华雪玲, 陈再生, 胡建达
中国当代儿科杂志 ›› 2019, Vol. 21 ›› Issue (7) : 690-695.
PDF(1561 KB)
PDF(1561 KB)
提高化疗强度对伴IKZF1基因缺失儿童急性淋巴细胞白血病预后的影响
Effect of increasing the intensity of chemotherapy on the prognosis of acute lymphoblastic leukemia in children with IKZF1 deletion
目的 总结伴IKZF1基因缺失儿童急性淋巴细胞白血病（ALL）的临床特征并观察提高化疗强度对其预后的影响。方法 2015年12月至2018年2月间确诊并按照中国儿童白血病协作组-ALL 2008（CCLG-ALL 2008）方案规范治疗的ALL患儿共278例，根据有无IKZF1基因缺失将其分为IKZF1基因缺失组和IKZF1基因正常组，IKZF1基因缺失组均接受CCLG-ALL 2008高危（HR）方案治疗，IKZF1基因正常组则按临床危险度分型接受不同强度化疗，比较两组的临床特征及无事件生存（EFS）率。结果 278例患儿中共24例（8.6%）检出IKZF1基因外显子大片段缺失。IKZF1基因缺失组初诊时WBC ≥ 50×109/L、BCR-ABL1融合基因阳性、诱导缓解治疗第15天微小残留病≥ 10%、微小残留病-HR、临床危险度-HR所占比例均高于IKZF1基因正常组（P < 0.05）。IKZF1基因缺失组3年EFS率（76%±10%）低于IKZF1基因正常组（84%±4%），但差异无统计学意义（P=0.282）；其中，IKZF1基因缺失组-非HR（实际按CCLG-ALL 2008 HR方案化疗）的预计3年EFS率为82%±12%，低于IKZF1基因正常组-非HR（86%±5%），但差异无统计学意义（P=0.436）。结论 伴IKZF1基因缺失的儿童ALL早期治疗反应更差，提高化疗强度可能改善其预后。
Objective To study the clinical features of acute lymphoblastic leukemia (ALL) in children with IKAROS family zinc finger 1 (IKZF1) deletion, and to observe the effect of increasing the intensity of chemotherapy on the prognosis of this disease. Methods A total of 278 children diagnosed with ALL between December 2015 and February 2018 were systematically treated according to the Chinese Children's Leukemia Group-ALL 2008 protocol (CCLG-ALL 2008). The patients were divided into an IKZF1-deleted group and a control group according to the presence or absence of IKZF1. The IKZF1-deleted group was treated with the regimen for high-risk group (HR) in the CCLG-ALL 2008 protocol, while the control group received different intensities of chemotherapy according to clinical risk classification. The clinical features and event-free survival rate (EFS) were compared between the two groups. Results A total of 24 (8.6%) cases of 278 children were found to have large deletions of exons of the IKZF1 gene. The IKZF1-deleted group had significantly higher proportions of cases with white blood cell count ≥ 50×109/L at initial diagnosis, BCR-ABL1 fusion gene positive, minimal residual disease ≥ 10% on the 15th day of induction remission treatment, minimal residual disease-high risk and clinical risk classification-high risk compared with the control group (P < 0.05). The 3-year EFS rate (76%±10%) in the IKZF1-deleted group was lower than that in the control group (84%±4%), but with no significant difference between the two groups (P=0.282). The estimated 3-year EFS rate in the IKZF1-deleted-non-HR group (actually treated with the chemotherapy regimen for HR in the CCLG-ALL 2008 protocol) was 82%±12%, which was lower than that in the control-non-HR group (86%±5%), but there was no significant difference (P=0.436). Conclusions ALL children with IKZF1 deletion have worse early treatment response, and increasing the intensity of chemotherapy might improve the prognosis.
急性淋巴细胞白血病 / IKZF1基因 / 化疗 / 预后 / 儿童
Acute lymphoblastic leukemia / IKZF1 gene / Chemotherapy / Prognosis / Child
[1] Dörge P, Meissner B, Zimmermann M, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol[J]. Haematologica, 2013, 98(3):428-432.
[2] Jia M, Wang ZJ, Li JY, et al. The impact of IKZF1 deletion on the prognosis of acute lymphoblastic leukemia:an updated meta-analysis[J]. Cancer Biomark, 2014, 14(6):493-503.
[3] Clappier E, Grardel N, Bakkus M, et al. IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy:results of the EORTC Children's Leukemia Group study 58951[J]. Leukemia, 2015, 29(11):2154-2161.
[4] Yeoh AEJ, Lu Y, Chin WHN, et al. Intensifying treatment of childhood B-lymphoblastic leukemia with IKZF1 deletion reduces relapse and improves overall survival:results of Malaysia-Singapore ALL 2010 Study[J]. J Clin Oncol, 2018, 36(26):2726-2735.
[5] 中华医学会儿科学分会血液学组, 《中华儿科杂志》编辑委员会. 儿童急性淋巴细胞白血病诊疗建议(第四次修订)[J]. 中华儿科杂志, 2014, 52(9):641-644.
[6] Olsson L, Johansson B. Ikaros and leukaemia[J]. Br J Haematol, 2015, 169(4):479-491.
[7] Marke R, Havinga J, Cloos J, et al. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia[J]. Leukemia, 2016, 30(7):1599-1603.
[8] Churchman ML, Low J, Qu C, et al. Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia[J]. Cancer Cell, 2015, 28(3):343-356.
[9] Marke R, van Leeuwen FN, Scheijen B. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia[J]. Haematologica, 2018, 103(4):565-574.
[10] Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1(Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse:a GIMEMA AL WP report[J]. J Clin Oncol, 2009, 27(31):5202-5207.
[11] Boer JM, van der Veer A, Rizopoulos D, et al. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia:an international collaborative study[J]. Leukemia, 2016, 30(1):32-38.
[12] Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia[J]. N Engl J Med, 2009, 360(5):470-480.
[13] Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros[J]. Nature, 2008, 453(7191):110-114.
[14] Iacobucci I, Storlazzi CT, Cilloni D, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients:on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP)[J]. Blood, 2009, 114(10):2159-2167.
[15] Volejnikova J, Mejstrikova E, Dörge P, et al. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2013, 60(3):420-427.
[16] Górniak P, Pastorczak A, Zalewska-Szewczyk B, et al. Polymorphism in IKZF1 gene affects age at onset of childhood acute lymphoblastic leukemia[J]. Leuk Lymphoma, 2014, 55(9):2174-2178.
[17] Olsson L, Ivanov Öfverholm I, Norén-Nyström U, et al. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013[J]. Br J Haematol, 2015, 170(6):847-858.
[18] Stanulla M, Dagdan E, Zaliova M, et al. IKZF1plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia[J]. J Clin Oncol, 2018, 36(12):1240-1249.
福建医科大学苗圃科研基金项目（2015MP022）；福建省血液医学中心建设项目[闽政办（2017）4号]。
